ManagedCareHemo.com Presents: A Rare Disease Strategy for the Evolving Hemophilia Treatment and Care Management Ecosystem: Rare Disease Payer Strategy Recommendations for Hemophilia


EXPERT FACULTY

Marla Feinstein, MPH, PhD
Senior Policy and Healthcare Analyst
National Hemophilia Foundation

James T. Kenney, RPh, MBA
Founder and President
JTKENNEY, LLC

Click here for biography

Shannon Carpenter, MD, MSCI, FAAP
Professor of Pediatrics, UMKC School of Medicine Hematology/Oncology,
Director Kansas City Regional Hemophilia Treatment Center
Director, Anticoagulation Management Program
Children’s Mercy Hospital

Click here for biography

Target Audience

This activity is designed to meet the educational needs of managed care pharmacy directors, clinical pharmacists, quality directors, medical directors, specialty pharmacists, care managers, registered nurses, and other managed care and payer organization professionals.

Statement of Need/Program Overview 

This activity can help managed care organizations and other payer types be better prepared to address the mounting challenges associated with rare, high-cost conditions such as hemophilia by formulating a comprehensive rare disease strategy. In doing so, it is necessary for payers to strike the appropriate balance between the urgency to respond to patient needs and the interpretation and application of the latest evidenced-based data while considering financial impact, value, and affordability, along with variation in coverage and its effects on access. This activity is designed to address these needs in order to improve clinical, economic, and humanistic outcomes for patients with hemophilia.

Educational Objectives 

After completing this activity, the participant should be better able to

Accreditation Statement 

In support of improving patient care, this activity has been planned and implemented by Medical Education Resources (MER), the National Hemophilia Foundation (NHF), and Impact Education, LLC. MER is jointly accredited by the Accreditation Council for Continuing Medical Education (ACCME), the Accreditation Council for Pharmacy Education (ACPE), and the American Nurses Credentialing Center (ANCC), to provide continuing education for the healthcare team.

Physician Credit
Medical Education Resources designates this live activity for a maximum of 0.75 AMA PRA Category 1 Credits™. Physicians should claim only the credit commensurate with the extent of their participation in the activity.

Nursing Credit
Medical Education Resources designates this live activity for a maximum of 0.75 ANCC nursing contact hours. Nurses will be awarded contact hours upon successful completion of the activity.

Medical Education Resources is a provider of continuing nursing education by the California Board of Registered Nursing, Provider #CEP 12299, for 0.75 contact hours.

Pharmacy Credit

Medical Education Resources (MER) designates this continuing education activity for 0.75 contact hour (0.075 CEUs) of the Accreditation Council for Pharmacy Education.

Universal Activity Number – JA0003680-9999-22-004-H01-P
This activity is certified as Knowledge-based CPE.

DISCLOSURE OF UNLABELED USE

This educational activity may contain discussion of published and/or investigational uses of agents that are not indicated by the FDA. The planners of this activity do not recommend the use of any agent outside of the labeled indications.

The opinions expressed in the educational activity are those of the faculty and do not necessarily represent the views of the planners. Please refer to the official prescribing information for each product for discussion of approved indications, contraindications, and warnings.


DISCLOSURE OF CONFLICTS OF INTEREST

Medical Education Resources ensures balance, independence, objectivity, and scientific rigor in all our educational activities. In accordance with this policy, MER identifies conflicts of interest with its instructors, content managers, and other individuals who are in a position to control the content of an activity. Conflicts are resolved by MER to ensure that all scientific research referred to, reported, or used in a continuing education activity conforms to the generally accepted standards of experimental design, data collection, and analysis. MER is committed to providing its learners with high-quality activities that promote improvements or quality in health care and not the business interest of a commercial interest.

The faculty reported the following financial relationships with commercial interests whose products or services may be mentioned in this activity:

Name of Faculty

Reported Financial Relationship

Marla Feinstein, PhD, MPH

No financial interest/relationships relating to the topic of this activity

James T. Kenney, RPh, MBA

No financial interest/relationships relating to the topic of this activity

Shannon Carpenter, MD, MSCI, FAAP

Consulting fees (ex. Ad boards) – Novo Nordisk, Kedrion, Genentech

The content managers reported the following financial relationships with commercial interests whose products or services may be mentioned in this activity:

Name of Content Manager

Reported Financial Relationship

MER Content Managers

No financial relationships to disclose.

Impact Education, LLC Staff

No financial relationships to disclose.

National Hemophilia Foundation Staff

No financial relationships to disclose.

DISCLAIMER

The content and views presented in this educational activity are those of the authors and do not necessarily reflect those of Medical Education Resources, Impact Education, LLC, the National Hemophilia Foundation and/or Sanofi Genzyme, Novo Nordisk, Inc., and Spark Therapeutics, Inc. The authors have disclosed if there is any discussion of published and/or investigational uses of agents that are not indicated by the FDA in their presentations. Before prescribing any medicine, primary references and full prescribing information should be consulted. Any procedures, medications, or other courses of diagnosis or treatment discussed or suggested in this activity should not be used by clinicians without evaluation of their patient’s conditions and possible contraindications on dangers in use, review of any applicable manufacturer’s product information, and comparison with recommendations of other authorities. The information presented in this activity is not meant to serve as a guideline for patient management.


METHOD OF PARTICIPATION AND REQUEST FOR CREDIT

There are no fees for participating and receiving CME/CE credit for this activity. During the period March 15, 2022 through September 30, 2023, participants must 1) read the learning objectives and faculty disclosures; 2) study the educational activity; 3) and complete the evaluation form. Upon completion of the full CME/CE activity, your certificate will be made available immediately to download and print.

For Pharmacists: Upon successfully completing the activity evaluation form, you may immediately submit your CPE credit to the NABP CPE Monitor Service. This may require you to add or update the e-profile ID/date of birth information saved in your account.

MEDIA

Internet

FEE INFORMATION

There is no fee for this educational activity.